CLINICAL TRIAL FACT SHEET

ELOQUENT - 1

ClinicalTrials.gov Identifier: NCT01335399

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Trial Description: A phase 3, randomized, open-label trial of lenalidomide (Revlimid®) /dexamethasone with or without elotuzumab (a monoclonal antibody formerly known as HuLuc63) in previously untreated multiple myeloma.

Trial Objectives: To determine whether the addition of elotuzumab to lenalidomide/low-dose dexamethasone will increase progression-free survival.

Assigned Interventions: Arm 1) lenalidomide + dexamethasone (active comparator arm);
Arm 2) lenalidomide + dexamethasone + elotuzumab (experimental arm)

Inclusion Criteria:

- 18 years of age or older
- Newly diagnosed patients with symptomatic myeloma who have not received any prior systemic anti-myeloma therapy AND have measurable disease AND are not candidates for high-dose therapy plus stem-cell transplantation because of age (≥65 years) or coexisting conditions

Exclusion Criteria:

- Subjects with non-secretory or oligo-secretory or free light-chain only myeloma
- Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Active plasma cell leukemia
- Positive hepatitis B, C, or Human Immunodeficiency Virus (HIV)

Currently Recruiting Locations and Telephone Contacts are shown on other side

For site information outside the United States, please contact clinical.trials@bms.com

International Myeloma Foundation
12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA
Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 (worldwide) • TheIMF@myeloma.org • myeloma.org

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

(continued)

Currently Recruiting Locations and Telephone Contacts:

For site information outside the United States, please contact clinical.trials@bms.com
(check clinicaltrials.gov for updates on site information)

Alabama

Birmingham Hematology & Oncology Associates
Birmingham, Alabama
Contact: Dr. Kevin S. Windsor, 205-803-4389

Arizona

Arizona Clinical Research Center, Inc.
Tucson, Arizona
Contact: Dr. Manuel R. Modiano, 520-290-2510

California

Alta Bates Summit Comprehensive Cancer Center
Berkeley, California
Contact: Dr. Rajesh Behl, 510-204-3428

Compassionate Cancer Care Medical Group
Corona, California
Contact: Dr. Haresh S. Jhangiani, 951-371-2411

Marin Cancer Care
Greenbrae, California
Contact: Dr. Peter D. Eisenberg, 415-925-5000

Medical Oncology Care Association
Orange, California
Contact: Dr. Birbal Bhaskar, 714-541-6622

Sharp Memorial Hospital
San Diego, California
Contact: Dr. Rajesh Belani, 858-637-7888

Connecticut

Yale University School of Medicine
New Haven, Connecticut
Contact: Dr. Madhav Dhodapkar, 203-785-4144/4191

Florida

Florida Cancer Specialists
Fort Myers, Florida
Contact: Dr. James Reeves, Jr., 239-274-9930

Florida Cancer Specialists and Research Institute
Gainesville, Florida
Contact: Dr. Peter Acs, 352-332-3900

Integrated Community Oncology Network
Orange Park, Florida
Contact: Dr. Mehdi Moezi, 904-272-3139

Palm Beach Cancer Institute
West Palm Beach, Florida
Contact: Dr. Shachar Peles, 561-366-4128

Pasco Hernando Oncology Associates
Brooksville, Florida
Contact: Dr. Raju Rao, 352-596-1401

Pasco Hernando Oncology Associates
New Port Richey, Florida
Contact: Dr. Kapisthalam S. Kumar, 727-842-2795

Illinois

Carle Foundation Hospital
Urbana, Illinois
Contact: Dr. James Egner, 217-383-301

University of Chicago Medical Center
Chicago, Illinois
Contact: Cara Rosenbaum, 773-702-0167

Indiana

Investigative Clinical Research of Indiana
Indianapolis, Indiana
Contact: Dr. Robert F Manges, 317-297-2208

Northern Indiana Cancer Research Consortium
South Bend, Indiana
Contact: Dr. Jose Bufill, 574-647-7390

Iowa

University of Iowa Hospitals and Clinics
Iowa City, Iowa
Contact: Dr. Raymond Hohl, 319-356-8110

Kentucky

Central Baptist Hospital
Lexington, Kentucky
Contact: Dr. Arvinda Padmanabhan, 859-276-0414

Louisiana

Cancer Center of Acadiana
Lafayette, Louisiana
Contact: Dr. Victoria Panelli, 337-289-8400

Willis-Kingston Cancer Center
Shreveport, Louisiana
Contact: Dr. Michael Moore, 318-212-8620

Maryland

Greater Baltimore Cancer Center
Baltimore, Maryland
Contact: Dr. Gary Cohen, 443-849-3051

The Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland
Contact: Dr. Stephen Noga, 443-777-7147

Massachusetts

Dana-Farber Cancer Institute
Boston, Massachusetts
Contact: Dr. Jacob Laubach, 617-582-7102

Michigan

Henry Ford Health System
Detroit, Michigan
Contact: Dr. Philip Kuriakose, 313-916-2772

Missouri

Capitol Comprehensive Cancer Care Clinic
Jefferson City, Missouri
Contact: Dr. Ali Khojestah, 573-442-6800

Mercy Medical Research Institute
Springfield, Missouri
Contact: Dr. V. Roger Holden, 417-820-9742

Washington University School of Medicine
St. Louis, Missouri
Contact: Dr. Keith Stockerl-Goldstein, 314-454-8304

New York

Beth Israel Comprehensive Cancer Center
New York, New York
Contact: Dr. Peter Wiernik, 212-636-3338

St. Luke's-Roosevelt Hospital Center
New York, New York
Contact: Dr. Peter Wiernik, 212-636-3338

North Carolina

Blumenthal Cancer Center
Charlotte, North Carolina
Contact: Dr. David W. Miller, 704-366-3001

Piedmont Hematology Oncology Associates
Winston-Salem, North Carolina
Contact: Dr. Franklin L. Chen, 336-277-8887

Ohio

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Contact: Dr. Christy Samaras, 216-445-2612

Cleveland Clinic Wooster Cancer Center
Wooster, Ohio
Contact: Christy Samaras, 330-287-4620

The Ohio State University Medical Center
Columbus, Ohio
Contact: Dr. Don Benson Jr., 614-293-8605

Signal Point Clinical Research Center, LLC
Middletown, Ohio
Contact: Dr. Nandagopal Vrindavanam

Oklahoma

Cancer Care Associates
Tulsa, Oklahoma
Contact: Dr. Charles Strnad, 918-292-8085

Pennsylvania

Oncology Hematology of Lehigh Valley
Bethlehem, Pennsylvania
Contact: Dr. Jack Faroun, 610-332-1485

Western Pennsylvania Hospital (Western Pennsylvania Cancer Institute)
Pittsburgh, Pennsylvania
Contact: Dr. Entezma Sahovic, 412-578-4355

South Carolina

Charleston Hematology Oncology Associates
Charleston, South Carolina
Contact: Dr. George F. Geils Jr., 843-266-2540

Tennessee

Baptist Hospital of East Tennessee
Knoxville, Tennessee
Contact: Dr. Tracy W. Dobbs, 865-934-2670

Tennessee Oncology
Nashville, Tennessee
Contact: Dr. Jesus Berdeja, 615-329-7274

Texas

Cancer Specialists of South Texas
Corpus Christi, Texas
Contact: Dr. Aftab Mahmood, 361-993-3456

Northwest Cancer Center
Houston, Texas
Contact: Dr. Laurent Gressot, 281-440-5006

The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Contact: Dr. Jatin Shah, 713-745-6130

Virginia

Hematology Oncology Associates of Fredericksburg
Fredericksburg, Virginia
Contact: Christopher Vaughn, 540-371-0079

Virginia Commonwealth University
Richmond, Virginia
Contact: Dr. Beata Holkova, 804-827-4994

Washington

Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact: William Bensinger, 206-667-5839

VA Puget Sound Health Care System
Seattle, Washington
Contact: Dr. Robert Richard, 206-277-3101

Washington, DC

Washington Cancer Center
Washington, DC
Contact: Dr. Joseph Catlett, 202-877-8839

West Virginia

Edwards Comprehensive Cancer Center
Huntington, West Virginia
Contact: Dr. Rajesh Sehgal, 304-399-6551

Wisconsin

Gundersen Clinic, Ltd
La Crosse, Wisconsin
Contact: Dr. Craig Cole, 608-782-7300

Dean Medical Center
Madison, Wisconsin
Contact: Dr. Amit Sanyal, 608-410-2700